Probiotics vs Microbiota-Based Medicines
Probiotics, live biotherapeutic products and fecal microbiota medicines are not the same. This page compares what each is, what trials show, how they are regulated and the risks.
Content last updated . This page has not been medically reviewed.
Definitions
- Probiotics are live microorganisms intended to have health benefits when consumed or applied to the body. They are found in yogurt and other fermented foods, supplements and beauty products. [1]
- Live biotherapeutic products (LBPs) is a regulatory term. FDA guidance on early trials covers LBPs, including some that are lawfully marketed as foods or dietary supplements and are proposed for clinical uses regulated as drugs. [2] See Live Biotherapeutic Products.
- Fecal microbiota products are made from donated human stool. For example, Vowst contains live bacteria and is manufactured from human fecal matter donated by qualified individuals. [3] See Fecal Microbiota-Based Therapies.
The difference at a glance
| Probiotic products | Approved fecal microbiota medicines | |
|---|---|---|
| Source | Specific named strains | Donated human stool, processed [3] |
| US regulatory route | Depending on intended use, may be regulated as a dietary supplement, food ingredient or drug; many are supplements sold without FDA approval [1] | FDA-listed biologics: Vowst (approved April 2023) and Rebyota [3][4] |
| Approved use | Products marketed as drugs must be approved through trials [1] | Preventing recurrence of C. difficile infection in adults 18 and over after antibiotic treatment [3][4] |
| Evidence level | Varies by strain and condition | Randomized trial evidence for that one use |
| Known risks | Severe or fatal infections reported in premature infants [1] | May carry a risk of transmitting infectious agents; may contain food allergens [3] |
What the research shows
Probiotics. NCCIH says probiotics have shown promise for several purposes and that much remains to be learned about whether they help or are safe for various conditions. [1] Effects depend on the strain: if one kind of Lactobacillus helps prevent an illness, that does not mean another kind would. [1] For C. difficile diarrhea during antibiotic treatment, a 2017 analysis of 31 studies concluded it is moderately certain that probiotics can reduce the risk, mostly in hospital patients. [1] Evidence label: promising but limited. Strain details are in Probiotic Strains and Labels.Fecal microbiota medicines. SER-109, an oral microbiome therapy, was tested in a randomized, double-blind, placebo-controlled phase 3 trial of 182 enrolled adults with repeated C. difficile infection. Recurrence within 8 weeks was 12% with the product and 40% with placebo, and the trial was funded by the manufacturer. [5] In the FDA's description of the trial behind Vowst's approval, recurrence through 8 weeks was 12.4% with Vowst versus 39.8% with placebo. [3] The most common side effects reported more often than with placebo were abdominal bloating, fatigue, constipation, chills and diarrhea. [3] Evidence label: approved medicine (FDA, for the indication above, read 2026-10-22).
Keep these apart
- A probiotic study does not show a fecal microbiota medicine works, and the reverse is also true.
- Approval of Vowst or Rebyota covers preventing recurrent C. difficile infection after antibiotics, not general gut health, and not other conditions. [3][4]
- A "microbiome" sold as a supplement is not the same as a licensed medicine. Do-it-yourself stool transfers are outside the scope of this page, and even a donor-screened product may carry a risk of transmitting infectious agents. [3]
Frequently asked questions
Is a fecal microbiota medicine just a strong probiotic?
No. Approved products such as Vowst are made from donated human stool and regulated as biologic medicines for a specific use. [3] Probiotics are usually specific strains and may be sold as supplements. [1]
What is Vowst approved for?
The FDA approved it to prevent recurrence of C. difficile infection in people 18 and older after antibacterial treatment for recurrent infection. [3]
Do probiotics prevent C. difficile?
A 2017 analysis of 31 studies concluded it is moderately certain that probiotics can reduce the risk of C. difficile diarrhea in people receiving antibiotics, mostly hospital patients. [1]
Are probiotics risk-free?
No. Severe or fatal infections have been reported in premature infants given probiotics. [1]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Who should check with a clinician first
Laws and approvals vary by country. This page describes the United States only, as read from FDA and NIH pages; it is not legal advice.
References
- NCCIH, Probiotics: Usefulness and Safety. Read 2026-10-22.
- FDA guidance, Early Clinical Trials With Live Biotherapeutic Products. Read 2026-10-22.
- FDA press announcement, approval of Vowst, 26 April 2023. Read 2026-10-22.
- FDA, REBYOTA product page. Read 2026-10-22.
- SER-109 phase 3 trial, NEJM 2022 (PubMed 35045228). Read 2026-10-22.